Bariatric surgery

record medical interest in obesity

Oprah & Ozempic; inevitable GLP-1 plateaus; record medical interest in obesity; compounded med controversy; pharma-based economic disruption.

Hello everyone, I hope you are well. We have some quite interesting news pieces this week, including reporting on Eli Lilly’s lawsuits against compounding pharmacies; record-setting interest in physicians applying to take the the American Board of Obesity Medicine (ABOM) exam; and, Oprah and a panel of obesity specialists diving into the GLP-1 topic. Also, […]

Oprah & Ozempic; inevitable GLP-1 plateaus; record medical interest in obesity; compounded med controversy; pharma-based economic disruption. Read More »

Over 70 companies in the obesity medications race

Over 70 companies in the obesity medications race; a new business model for weight management; obesity in youths as a public health emergency; a 40% reduction in blood cancers after bariatric surgery

Hello everyone, I hope you are enjoying this weekend, one where — at least in much of the US Northeast — the weather is feeling like the first crisp glimpses of autumn [though I note that, if you were exposed to Hurricane Lee, it may be wet and windy, and with the inconvenience of power

Over 70 companies in the obesity medications race; a new business model for weight management; obesity in youths as a public health emergency; a 40% reduction in blood cancers after bariatric surgery Read More »

Bariatric surgery

The future – or not – of bariatric surgery; access disparities in GLP-1 medications (and taking second jobs to pay for them); cost per avoided cardiovascular death; and, are bacteria the new Ozempic?

Hello everyone, Welcome to September; I hope you are well on this long Labour Day weekend in North America. [And I will note, Labour Day is celebrated in many more places around the world than just the US and Canada, though it is more commonly celebrated on May 1st and alternately or also known as

The future – or not – of bariatric surgery; access disparities in GLP-1 medications (and taking second jobs to pay for them); cost per avoided cardiovascular death; and, are bacteria the new Ozempic? Read More »

Bariatric surgery cuts cancer risk by 25%, obesity as a key public health threat in the US, only 9% of anti-obesity meds prescriptions are filled, and payer strategies for GLP-1 drugs.

Bariatric surgery cuts cancer risk by 25%, obesity as a key public health threat in the US, only 9% of anti-obesity meds prescriptions are filled, and payer strategies for GLP-1 drugs.

Hello everyone, I hope you are all enjoying a late summer weekend with family and friends. Key items this week have included news of a 25% reduction in the risk of cancer after bariatric surgery; that only 9% of prescriptions for obesity medicines were filled over 60 days; that obesity is believed to be one

Bariatric surgery cuts cancer risk by 25%, obesity as a key public health threat in the US, only 9% of anti-obesity meds prescriptions are filled, and payer strategies for GLP-1 drugs. Read More »

The Golden Age of Medicine; GLP-1 drugs are “having a moment…”; impressive data from trials; and multimodal approaches to align with surgical therapies.

Hello everyone, I hope you are enjoying the weekend, staying clear of wildfire smoke, and preparing for July 4th: Happy Independence Day! (And, it must be said, my condolences to my fellow Brits!). This has been quite a week on the obesity treatment front, with a ton on new drugs in the pipeline announced and

The Golden Age of Medicine; GLP-1 drugs are “having a moment…”; impressive data from trials; and multimodal approaches to align with surgical therapies. Read More »

A bumper two-week review, with Noom on GLP-1s, Chrissy Farr and Rock Health review metabolic health, bariatric surgery in teens, and more.

A bumper two-week review, with Noom on GLP-1s, Chrissy Farr and Rock Health review metabolic health, bariatric surgery in teens, and more.

AT A GLANCE Noom, a behavior change platform, announces a new program — “Noom Med” — to incorporate anti-obesity medications. Restriction of access to Ozempic and Wegovy, by ‘…employers’ health plans [who] won’t pay for them…’, is covered by The Wall Street Journal. Rock Health focuses on whole person view of obesity care, to comprise a serviceable addressable market of almost $13B. Sima Sistani,

A bumper two-week review, with Noom on GLP-1s, Chrissy Farr and Rock Health review metabolic health, bariatric surgery in teens, and more. Read More »

Bariatric surgery and GLP-1s, Eli Lilly reports new data on Mounjaro (tirzetapide), and Chelsea Clinton on global obesity perspectives across metabolic and obesity care – 430

Bariatric surgery and GLP-1s, Eli Lilly reports new data on Mounjaro (tirzetapide), and Chelsea Clinton on global obesity: perspectives across metabolic and obesity care – 4/30

AT A GLANCE… At the Fortune Brainstorm Health conference, I put Chelsea Clinton on the spot for her suggestions to manage the looming four billion people across the globe who will be living with obesity by the year 2035. In The Atlantic, Yasmin Tayag leads with ‘We’ve had a cheaper, more potent Ozempic alternative for decades…’ on bariatric surgery ‘…to be the

Bariatric surgery and GLP-1s, Eli Lilly reports new data on Mounjaro (tirzetapide), and Chelsea Clinton on global obesity: perspectives across metabolic and obesity care – 4/30 Read More »

Scroll to Top
Skip to content